Global Downstream Market 2024–2033

Reports Description

As per the current market research conducted by CMI Team, the global Downstream Market is expected to record a CAGR of 14.2% from 2023 to 2032. In 2022, the market size is projected to reach a valuation of USD 28.5 billion. By 2032, the valuation is anticipated to reach USD 76.8 billion.

The downstream market involves the purification and isolation of biopharmaceutical products from biological sources to ensure product quality, safety, and efficacy. It encompasses a series of separation, purification, and filtration techniques that transform raw materials into final biopharmaceutical products.

The market is dynamic, driven by the biopharmaceutical industry's need for efficient and scalable downstream processing solutions to meet global healthcare demands. Advancements in technology and regulatory compliance contribute to the market's evolving nature.

Key trends include the adoption of continuous bioprocessing, digitalization for improved efficiency, diversification of supply chains, and an emphasis on sustainability. Personalized medicine and increased outsourcing also shape the downstream processing landscape, facilitating innovation and responsiveness to changing market demands.

To learn more about this report - request a sample report PDF

Downstream Market - Significant Growth Factors

The Downstream Market presents significant growth opportunities due to several factors:

• Technological Advancements: Continuous innovations and technological advancements in downstream processing are revolutionizing the biopharmaceutical industry. Cutting-edge solutions like single-use systems, high-throughput chromatography, and automated platforms enhance process efficiency, scalability, and product quality. These advancements facilitate faster production timelines, reduced operational costs, and improved bioprocessing capabilities, attracting widespread adoption across the market.

• Rising Biotechnology Investments: The burgeoning investments in biotechnology research and development are instrumental in expanding the downstream market. The continuous influx of funds into biopharmaceutical companies and research institutions fuels biologics production, necessitating sophisticated downstream processing solutions to optimize yields, purification, and product recovery.

• Stringent Regulatory Requirements: The stringent and evolving regulatory landscape surrounding biopharmaceutical manufacturing and quality control mandates the use of advanced downstream processing methods. Compliance with strict regulatory standards regarding product quality, safety, and purity becomes paramount, encouraging biopharmaceutical companies to seek reliable and compliant downstream processing solutions.

• Growing Biomanufacturing Outsourcing: The escalating trend of outsourcing biopharmaceutical production to contract manufacturing organizations (CMOs) opens doors of opportunity for downstream processing companies. As CMOs seek specialized and adaptable downstream processing services and technologies, companies in the market can tailor their offerings to meet the unique requirements and specific needs of diverse CMOs.
• Rising Demand for Biologics: The remarkable surge in the demand for biologics, including monoclonal antibodies, gene therapies, and cell-based therapies, presents an expansive opportunity for downstream processing companies. As the complexity and diversity of biologics increase, there is a growing need for innovative and customized downstream processing solutions to handle these intricate products efficiently, ensuring their consistent production and reliable delivery to patients.

Downstream Market - Mergers and Acquisitions

The Downstream Market has seen several mergers and acquisitions in recent years, with companies seeking to expand their market presence and leverage synergies to improve their product offerings and profitability. Some notable examples of mergers and acquisitions in the Downstream Market include:

• Merck KGaA, Darmstadt, Germany, and BioNTech: In 2021, Merck KGaA, Darmstadt, Germany, and BioNTech are further expanding their strategic partnership. Merck KGaA, Darmstadt, Germany, in close collaboration with BioNTech, will significantly accelerate the supply of urgently needed lipids and increase the amount of lipid delivery towards the end of 2021. The lipids will be used for the production of the Pfizer-BioNTech Covid-19 Vaccine (BNT162b2).

• Danaher Corporation's Acquisition of Cytiva: In 2020 Danaher Corporation, a multinational conglomerate, acquired Cytiva, a bioprocessing solutions provider, from General Electric Company (GE). The acquisition expanded Danaher's downstream processing capabilities, offering a comprehensive portfolio of bioprocessing products, including chromatography resins and single-use systems.

• Repligen Corporation Acquire ARTeSYN Biosolutions: Repligen Corporation, a leading bioprocessing solutions provider, has announced an agreement to acquire ARTeSYN Biosolutions, a renowned innovator in bioprocess systems. The acquisition represents a strategic move by Repligen to expand its portfolio of upstream and downstream bioprocessing technologies.

• Thermo Fisher Scientific Inc.'s Acquisition of Brammer Bio: In 2019 Thermo Fisher Scientific, a scientific services company, acquired Brammer Bio, a gene and cell therapy contract development and manufacturing organization (CDMO). The acquisition expanded Thermo Fisher's capabilities in downstream processing and gene therapy production, providing end-to-end solutions for biopharmaceutical customers.

These mergers and acquisitions have helped companies expand their product offerings, improve their market presence, and capitalize on growth opportunities in the Downstream Market. The trend is expected to continue as companies seek to gain a competitive edge in the market.

COMPARATIVE ANALYSIS OF THE RELATED MARKET

Downstream Market - Significant Threats

The Downstream Market faces several significant threats that could impact its growth and profitability in the future. Some of these threats include:

• High Capital Investment: The downstream market demands significant initial capital investment for setting up advanced purification technologies, single-use systems, and automated platforms. This high cost of entry can deter new players from entering the market, limiting competition and potentially leading to monopolistic practices among established players.

• Biological Contamination Risks: The risk of biological contamination during downstream processing can lead to batch failures and production delays, jeopardizing product quality and safety. Contamination incidents can result in costly recalls, regulatory penalties, and damage to the company's reputation.

• Competition from Emerging Technologies: Emerging technologies in upstream processing, such as cell culture innovations and bioreactor advancements, may impact downstream processing demand. Improved upstream processes can lead to higher yields and purity, reducing the reliance on downstream purification, thereby posing a threat to traditional downstream processing approaches.

• Stringent Regulatory Compliance: The complex and ever-changing regulatory landscape in biopharmaceutical manufacturing poses a significant threat to downstream processing companies. Strict adherence to various regulatory requirements, including Good Manufacturing Practices (GMP), can be challenging and costly, leading to potential compliance breaches and reputational risks.

Report Scope

Category-Wise Insights

By Product:

• Centrifuges: Centrifuges are downstream processing equipment used to separate and clarify biomolecules by subjecting them to centrifugal force. Trends include the development of high-speed and continuous centrifuges, enhancing separation efficiency and reducing processing time.

• Dryers: Dryers remove moisture from biopharmaceutical products after purification. Trends focus on energy-efficient and aseptic drying technologies, ensuring product stability and minimizing environmental impact.

• Chromatography Systems: Chromatography systems separate and purify biomolecules based on their interactions with stationary phases. Trends include continuous chromatography and advanced resins, streamlining purification and improving product yields.

• Filters and Evaporators: Filters remove impurities, while evaporators concentrate solutions during downstream processing. Trends encompass single-use and self-cleaning filters, along with energy-efficient evaporators for sustainable manufacturing.

• Others: This category includes diverse downstream processing equipment and solutions that do not fall under the specific product types. Trends may encompass automation, digitalization, and artificial intelligence integration to optimize the overall downstream processing workflow.

By Application

• Antibodies Production: Downstream processing for antibodies production involves purification and isolation of monoclonal or polyclonal antibodies from biological sources. Trends include adoption of single-use systems, high-throughput chromatography, and continuous bioprocessing, enabling efficient production of therapeutic antibodies with enhanced purity and yield.

• Antibiotic Production: Downstream processing in antibiotic production includes isolation and purification of antibiotics from microbial fermentation. Trends focus on advanced filtration, chromatography, and automation technologies to optimize antibiotic recovery, ensuring high-quality and potent antibiotics for pharmaceutical applications.

• Hormone Production: Downstream processing for hormone production involves purification and isolation of hormones from genetically modified cells or organisms. Trends encompass continuous bioprocessing and digitalization, enhancing productivity, accuracy, and consistency in hormone purification, catering to diverse medical and industrial applications.

• Enzyme Production: Downstream processing in enzyme production comprises purification and recovery of enzymes from microbial or recombinant sources. Trends emphasize single-use technologies, high-performance chromatography, and process intensification, facilitating efficient enzyme purification with improved stability and activity for various industrial processes.

• Vaccine Production: Downstream processing for vaccine production involves purification and formulation of viral or bacterial antigens from cell cultures or fermentation. Trends include single-use systems, continuous bioprocessing, and data analytics, streamlining vaccine purification and formulation processes, contributing to faster vaccine development and production.

By Technique

• Purification by Chromatography: Purification technique in downstream processing that separates and purifies biomolecules based on their specific interactions with chromatographic media. The process involves selective binding and elution of target molecules, ensuring high product purity and yield.

• Solid-Liquid Separation: Technique used to separate solid particles from liquid suspensions during downstream processing. Methods like centrifugation, filtration, and sedimentation are employed to remove impurities and concentrate target biomolecules.

• Cell Disruption: Downstream technique used to break open cells and release intracellular biomolecules for further processing. Methods like mechanical disruption, enzymatic lysis, and high-pressure homogenization are employed.

• Concentration: Technique to increase the concentration of target biomolecules by removing excess water or diluents, enhancing product yield and reducing volume for downstream processing.

• Formulation: Process of developing the final product formulation, including buffer optimization, pH adjustment, and stabilization, ensuring product stability and suitability for end-use applications.

Downstream Market - Regional Analysis

The Downstream Market is segmented into various regions, including North America, Europe, Asia-Pacific, and LAMEA. Here is a brief overview of each region:

• North America: Trends in North America's Downstream market include a strong focus on continuous bioprocessing and single-use technologies, driven by the region's advanced biopharmaceutical industry. Biomanufacturers in North America prioritize process intensification to improve productivity and reduce costs. Dominating market players in this region include Thermo Fisher Scientific Inc., Merck KGaA, and General Electric Company (GE Healthcare), known for their innovative downstream processing solutions and strong market presence.

• Europe: In Europe, the Downstream market trends revolve around sustainability initiatives and the adoption of environmentally friendly bioprocessing techniques. The region emphasizes automation and digitalization to optimize manufacturing processes, ensuring compliance with stringent regulatory standards. Key players in Europe's market include Sartorius AG, Danaher Corporation (Pall Corporation), and 3M Company (3M Purification Inc.), renowned for their cutting-edge technologies and commitment to sustainability.

• Asia-Pacific: Asia-Pacific's Downstream market experiences significant growth due to the region's expanding biopharmaceutical sector. Key trends include a rising demand for biologics and increasing investments in advanced biomanufacturing technologies. Asia-Pacific also witnesses a surge in contract manufacturing and outsourcing services. Dominating market players in this region are Repligen Corporation, Agilent Technologies, Inc., and Eppendorf AG, known for their wide product portfolios and expertise in bioprocessing technologies.

• LAMEA (Latin America, Middle East, and Africa): In LAMEA, the Downstream market is marked by a growing focus on personalized medicine and the production of biologics for local healthcare needs. The region experiences increasing partnerships and collaborations between local biopharmaceutical companies and global players. Dominating market players in LAMEA include MilliporeSigma (Sigma-Aldrich Corporation), Avantor, Inc., and GE Healthcare, known for their contributions to the region's biopharmaceutical growth and market presence.

Competitive Landscape – Downstream Market

The Downstream Market is highly competitive, with a large number of manufacturers and retailers operating globally. Some of the key players in the market include:

• Thermo Fisher Scientific Inc.
• Merck KGaA
• General Electric Company (GE Healthcare)
• Sartorius AG
• Danaher Corporation (Pall Corporation)
• 3M Company (3M Purification Inc.)
• Repligen Corporation
• Agilent Technologies Inc.
• Eppendorf AG
• MilliporeSigma (Sigma-Aldrich Corporation)
• Others

These companies operate in the market through various strategies such as product innovation, mergers and acquisitions, and partnerships.

Several new players have entered the Downstream market, adopting innovation and development to establish their presence. These emerging companies focus on niche downstream processing solutions, such as continuous chromatography systems, single-use technologies, and digitalization for process optimization.

By offering cutting-edge and specialized solutions, these new entrants aim to cater to specific industry needs, creating opportunities for market disruption and competition. Several new players have entered the Downstream market, adopting innovation and development to establish their presence.

These emerging companies focus on niche downstream processing solutions, such as continuous chromatography systems, single-use technologies, and digitalization for process optimization. By offering cutting-edge and specialized solutions, these new entrants aim to cater to specific industry needs, creating opportunities for market disruption and competition.

Regional Coverage

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America